Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | TP53 | P04637 | 2/20 | 0.84 |
| ▸ | MAPT | P10636 | 1/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.84 |
| ▸ | ACHE | P22303 | 5/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.53 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.53 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.53 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 2/20 | 0.52 |
| ▸ | HINT1 | P49773 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3478703 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL1120556 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL278443 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL1120553 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL313898 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13924747 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13296259 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL3427712 | 1.00 | LMNA (0.84) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL6363586 | 0.95 | LMNA (0.76) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL17198377 | 0.93 | ALDH1A1 (0.73) | LMNAALDH1A1TP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2669292-B1 | RIBOFURANOSYL PURINE COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH PLATELET AGGREGATION | BEIJING KBD PHARMACEUTICALS CO LTD (CN) | 2017-03-29 | — | — | EP | disclosed |
| US-9493502-B2 | Ribofuranosyl purine compounds, methods for preparing the same and use thereof | BEIJING KBD PHARMACEUTICALS CO., LTD. (CN) | 2016-11-15 | — | — | US | disclosed |
| US-20160311844-A1 | RIBOFURANOSYL PURINE COMPOUNDS, METHODS FOR PREPARING THE SAME AND USE THEREOF | UNIV BEIJING CHEMICAL TECH (CN) | 2016-10-27 | — | — | US | disclosed |
| US-20140005138-A1 | Ribofuranosyl Purine Compounds, Methods for Preparing the Same and Use Thereof | BEIJING KBD PHARMACEUTICALS CO., LTD. (CN) | 2014-01-02 | — | — | US | disclosed |
| EP-2669292-A1 | RIBOFURANOSYL PURINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing University of Chemical Technology (CN) | 2013-12-04 | — | — | EP | disclosed |
| EP-2221311-B1 | Novel nucleic acid base pair | TAGCYX BIOTECHNOLOGIES (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1943251-B8 | A1 ADENOSINE RECEPTOR AGONISTS | GILEAD PALO ALTO INC (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1943251-B1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-1114827-B1 | NOVEL NUCLEIC ACID BASE PAIR | JAPAN SCIENCE & TECH AGENCY (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-5484774-A | 2, N6 -disubstituted adenosines, tri-O-ester derivatives and their pharmaceutical compositions to treat ischemias | NOVO NORDISK A/S (DK) | 1996-01-16 | — | — | US | disclosed |
| EP-0508687-B1 | ATP analogues | FISONS PLC (GB) | 1995-09-13 | — | — | EP | disclosed |
| EP-0664294-A1 | Production of nucleoside analogues | Reese, Colin (GB) | 1995-07-26 | — | — | EP | disclosed |
| US-5432164-A | Anticonvulsants | NOVO NORDISK A/S (DK) | 1995-07-11 | — | — | US | disclosed |
| US-5430027-A | 2-chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias | NOVO NORDISK A/S (DK) | 1995-07-04 | — | — | US | disclosed |
| EP-0609375-A1 | NOVEL 2,6-DISUBSTITUTED PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-08-10 | — | — | EP | disclosed |
| EP-0607367-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993023417-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993008206-A1 | NOVEL 2,6-DISUBSTITUTED PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-04-29 | — | — | WO | disclosed |
| EP-0508687-A1 | ATP analogues | Astra Pharmaceuticals Limited (GB) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311844-A1 | RIBOFURANOSYL PURINE COMPOUNDS, METHODS FOR PREPARING THE SAME AND USE THEREOF | NUDT1, ITPA, HPRT1 | LMNA 1129/4885ALDH1A1 340/4885TP53 2612/4885 |
| US-20140005138-A1 | Ribofuranosyl Purine Compounds, Methods for Preparing the Same and Use Thereof | NUDT1, ITPA, HPRT1 | LMNA 1129/4885ALDH1A1 340/4885TP53 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.